We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for Dell Technologies' (DELL) Q1 Earnings?
Read MoreHide Full Article
Dell Technologies (DELL - Free Report) is set to release first-quarter fiscal 2020 results on May 30.
In the last reported quarter, the company posted non-GAAP net income of $1.6 billion, up 26% year over year.
Revenues increased 8% year over year to $24.01 billion and surpassed the Zacks Consensus Estimate of $23.46 billion. The increase in revenues was driven by double-digit growth in servers, VMware and expanding commercial client user base.
The Zacks Consensus Estimate for earnings has declined 2.5% to $1.15 over the past 30 days. The consensus mark for revenues is $22.50 billion, implying growth of 5.4% from the figure reported in the year-ago quarter.
Let’s see how things are shaping up for this announcement.
Factors to Watch
Dell is expected to benefit from its dominant position in the enterprise IT solutions market. Strong spending by customers on infrastructure is expected to be a key catalyst for the company in the to-be-reported quarter.
The company is also likely to gain from the ongoing momentum at VMware, in which it has a majority stake. Dell also own stakes in Pivotal Software and SecureWorks.
Moreover, Dell continues to gain share in the PC market, per Gartner. The company was ranked third by Gartner and recorded fifth consecutive quarter of PC shipment growth in first-quarter 2019. Dell’s 17.6% market share in the period under consideration grew year over year, up from 16% in the year-ago quarter.
However, a sluggish PC market doesn’t bode well for the company. Moreover, Dell’s focus on high-end notebooks and gaming negatively impacts its consumer business, revenues of which declined 6% year over year to $3.1 billion in the last reported quarter.
Additionally, the company faces stiff competition in the server and data storage equipment market from the likes of HP and Hewlett Packard Enterprise (in on-premise hardware).
Dell Partners with Microsoft
Last month, Dell and Microsoft (MSFT - Free Report) announced an extension to their partnership that now includes VMware.
Azure VMware Solutions, the result of the expanded partnership, allow customers to migrate, extend and run existing VMware workloads from on-premises environments to Azure seamlessly.
Moreover, Microsoft 365 and VMware Workspace ONE common users are expected to benefit from the cross-platform integrations.
However, since the deal was signed later in the quarter, it is expected to have no material impact on Dell’s to-be-reported quarterly results.
What Our Model Says
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) along with a positive Earnings ESP has a good chance of beating estimates. The Sell-rated stocks (Zacks Rank #4 or 5) are best avoided.
Dell has a Zacks Rank #3 and an Earnings ESP of +13.91%. You can uncover the best stocks to buy or sell, before they’re reported, with our Earnings ESP Filter.
Another Stock with Favorable Combination
Here is another stock you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
What's in the Cards for Dell Technologies' (DELL) Q1 Earnings?
Dell Technologies (DELL - Free Report) is set to release first-quarter fiscal 2020 results on May 30.
In the last reported quarter, the company posted non-GAAP net income of $1.6 billion, up 26% year over year.
Revenues increased 8% year over year to $24.01 billion and surpassed the Zacks Consensus Estimate of $23.46 billion. The increase in revenues was driven by double-digit growth in servers, VMware and expanding commercial client user base.
Dell Technologies Inc. Price and EPS Surprise
Dell Technologies Inc. price-eps-surprise | Dell Technologies Inc. Quote
The Zacks Consensus Estimate for earnings has declined 2.5% to $1.15 over the past 30 days. The consensus mark for revenues is $22.50 billion, implying growth of 5.4% from the figure reported in the year-ago quarter.
Let’s see how things are shaping up for this announcement.
Factors to Watch
Dell is expected to benefit from its dominant position in the enterprise IT solutions market. Strong spending by customers on infrastructure is expected to be a key catalyst for the company in the to-be-reported quarter.
The company is also likely to gain from the ongoing momentum at VMware, in which it has a majority stake. Dell also own stakes in Pivotal Software and SecureWorks.
Moreover, Dell continues to gain share in the PC market, per Gartner. The company was ranked third by Gartner and recorded fifth consecutive quarter of PC shipment growth in first-quarter 2019. Dell’s 17.6% market share in the period under consideration grew year over year, up from 16% in the year-ago quarter.
However, a sluggish PC market doesn’t bode well for the company. Moreover, Dell’s focus on high-end notebooks and gaming negatively impacts its consumer business, revenues of which declined 6% year over year to $3.1 billion in the last reported quarter.
Additionally, the company faces stiff competition in the server and data storage equipment market from the likes of HP and Hewlett Packard Enterprise (in on-premise hardware).
Dell Partners with Microsoft
Last month, Dell and Microsoft (MSFT - Free Report) announced an extension to their partnership that now includes VMware.
Azure VMware Solutions, the result of the expanded partnership, allow customers to migrate, extend and run existing VMware workloads from on-premises environments to Azure seamlessly.
Moreover, Microsoft 365 and VMware Workspace ONE common users are expected to benefit from the cross-platform integrations.
However, since the deal was signed later in the quarter, it is expected to have no material impact on Dell’s to-be-reported quarterly results.
What Our Model Says
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) along with a positive Earnings ESP has a good chance of beating estimates. The Sell-rated stocks (Zacks Rank #4 or 5) are best avoided.
Dell has a Zacks Rank #3 and an Earnings ESP of +13.91%. You can uncover the best stocks to buy or sell, before they’re reported, with our Earnings ESP Filter.
Another Stock with Favorable Combination
Here is another stock you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat.
Science Applications International (SAIC - Free Report) has an Earnings ESP of +8.50% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>